Keywords: AstraZeneca, Ardea Biosciences, M&A, Gout drug, Lesinurad

AstraZeneca to acquire Ardea Bio for $1.26 billion

Article | 23 April 2012

Print This

In line with its stated policy of making strategic, rather than mega, acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in